Strengthening CAR-T Therapy to Work Against Solid Tumors
Retrieved on:
Mittwoch, Mai 8, 2024
Immunotherapy, Brain, University, Blood, Prostate, Protein, Mouse, Pancreas, Ovary, Safety, Public health, See, Cancer research, Glioblastoma, Genetic engineering, Invention, TMIGD2, Canadian Aviation Regulations, Urology, National Cancer Institute, Research, Leukemia, Chimera, Lymphoma, CD276, Liver, Microbiology, Medicine, Bone marrow, Neoplasm, Lung, Paper, Antigen, Zang, Immune system, Albert Einstein, Vaccine
"CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.
Key Points:
- "CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.
- "We found that our changes to standard CAR-T cell therapy can significantly boost its effectiveness against solid tumors, including often-fatal pancreatic cancer and glioblastomas."
- Dr. Zang and his colleagues created five CAR-T therapies that they tested on mice implanted with several types of solid human tumors.
- He later realized that incorporating TMIGD2 into CAR-T cells might enable them to overcome the challenges posed by solid tumors.